Bristol Myers Squibb (NYSE: BMY) stock closed at $60.93 on July 21, up 1.28% on the day. The previous day, the company announced the integration of NVIDIA’s DGX SuperPOD (with the DGX Vera Rubin NVL72 system) to enhance its AI capabilities, aiming to advance research programs in oncology and immunology.
Bristol Myers Squibb and NVIDIA DGX SuperPOD Partnership Announcement
Based on market data for July 21, 2026, BMY stock closed at $60.93, up 1.28% from the prior trading day. The day before (July 20), Bristol Myers Squibb announced the integration of NVIDIA DGX SuperPOD (with the DGX Vera Rubin NVL72 system) to enhance its AI computing power. This is intended to improve the efficiency of drug R&D in areas such as oncology and immunology.
According to NVIDIA’s official description, the DGX SuperPOD is expected to deliver a 10x increase in computing power per megawatt over the previous generation, helping manage complex tasks in drug development and research.
BMY Core Product Portfolio: Eliquis, Opdivo, and CAR-T Therapies
Bristol Myers Squibb’s core drug portfolio includes the following key products:
Eliquis: an oral anticoagulant used for stroke prevention in patients with atrial fibrillation and for the treatment of venous thromboembolism. It is BMY’s most important revenue source for its cardiovascular business, co-developed by BMY and its partners
Opdivo: a PD-1 immune checkpoint inhibitor expanded to multiple cancer indications, including lung cancer, melanoma, and renal cell carcinoma, serving as a core pillar of BMY’s oncology business
Abecma (idecabtagene vicleucel): a CAR-T cell therapy targeting hematologic malignancies, obtained after the acquisition of Celgene
Breyanzi (lisocabtagene maraleucel): another CAR-T therapy for relapsed or refractory hematologic malignancies
GuruFocus Data: GF Score 78, No Insider Buys in Three Months
According to GuruFocus’s latest data, BMY’s main quantitative indicators are as follows: GF Score 78/100 (GuruFocus proprietary score, indicating strong overall performance); GF Value $55.11 (based on its proprietary valuation model, indicating BMY’s current share price is slightly overvalued); market cap of about $124.04 billion; and the U.S. market accounts for about 70% of sales.
In terms of insider activity, there were no insider buy records in the past three months, but in the past year there were three insider sell transactions totaling about $4.52 million.
FAQ
What were the closing price and daily gain for Bristol Myers Squibb’s BMY stock on July 21?
Based on market data for July 21, 2026, BMY stock closed at $60.93, up 1.28% on the day.
What technologies are involved in the AI collaboration between Bristol Myers Squibb and NVIDIA?
According to the July 20, 2026 announcement, Bristol Myers Squibb integrated NVIDIA DGX SuperPOD (with the DGX Vera Rubin NVL72 system). The DGX SuperPOD is expected to improve computing power per megawatt by 10x versus the previous generation, aiming to advance R&D programs in oncology and immunology.
How does GuruFocus evaluate BMY’s GF Score and valuation?
Based on GuruFocus data, BMY has a GF Score of 78/100 and a GF Value of $55.11, indicating the current share price is slightly overvalued; market cap is about $124.04 billion.
